8-K current report · filed Nov 9, 2026

Definium Therapeutics, Inc. (DFTX) 8-K Current Report: November 9, 2026

Item 2.02Item EX-99.1DFTX overview

Short answer

Definium Therapeutics, Inc. (DFTX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal quarter ended September 30, 2026 results announced on November 9, 2026.

Definium Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal quarter ended September 30, 2026 results announced on November 9, 2026
  • Press release includes recent corporate highlights and conference call information
  • Investors should review Exhibit 99.1 for financial figures and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Positive Phase 3 Voyage and Panorama results in GAD, with placebo-adjusted HAM-A improvements of 5.4 and 5.1 points
  • DT120 ODT received FDA Breakthrough Therapy designation for MDD, supporting regulatory momentum toward a first-half 2027 NDA filing
  • Cash, equivalents and investments reached approximately $1.05B, up from $411.6M, with funding projected into 2030
  • Third-quarter R&D expense rose to $46.1M and G&A to $26.1M, reflecting late-stage development and commercialization preparation
  • DT402 showed exploratory improvements in five-adult ASD study, but statistical conclusions were not possible; multi-dose study planned for 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Definium Therapeutics, Inc. 8-K filings

Get the next DFTX 8-K as it lands

Follow DFTX for push alerts, or ask the research agent what this filing means.